Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DLST RNAi
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous, Inhalation, Intrathecal, Topical, Ophthalmic, Intratumoral, Intralesional, Intravitreal, Parenteral, Implant
01
Overview
DLST RNAi refers to the use of RNA interference (RNAi) to suppress the expression of dihydrolipoamide S-succinyltransferase (DLST), the E2 component of the alpha-ketoglutarate dehydrogenase complex (KGDHC). DLST plays a vital role in the tricarboxylic acid (TCA) cycle by converting alpha-ketoglutarate to succinyl-CoA. Research presented at AACR 2016 demonstrated that DLST is essential for the survival and pathogenesis of MYC-driven T-cell acute lymphoblastic leukemia (T-ALL). Knockdown of DLST in human T-ALL cell lines leads to metabolic disruption, including the accumulation of alpha-ketoglutarate and glutamine, resulting in decreased cell viability and the induction of apoptosis. This metabolic dependency suggests that DLST is a potential therapeutic target for MYC-mediated hematological malignancies.
- Other names
- DLST siRNADLST shRNA
02
Targets
OGDH (Dihydrolipoamide S-succinyltransferase)TLR3 (Toll-like receptor 3)TLR7/8 (Toll-like receptor 7 and Toll-like receptor 8)IFIH1 (MDA5)
Beyond the preview
Go deeper on DLST RNAi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DLST RNAi.